Sign up USA
Proactive Investors - Run By Investors For Investors

Biogen Idec and Roche Meet Primary Endpoint on Phase III Study into Rheumatoid Arthritis Treatment

Biogen Idec and Roche Meet Primary Endpoint on Phase III Study into Rheumatoid Arthritis Treatment

Biogen Idec (NASDAQ: BIIB) and Roche Group (OTC: RHHBY, SIX: RO) subsidiary Genentech announced their Phase III study into a treatment for rheumatoid arthritis (RA) patients had met its primary endpoint.


Rheumatoid Arthritis is a debilitating auto-immune disease that affects an estimated 1.3 million Americans. The damage that occurs in RA is a result of the immune system attacking joint tissue, causing painful chronic inflammation and irreversible damage. The disease often results in disability.


"These results are significant because they are the first data from a large Phase III trial to show that a humanized antibody targeted at B-cells improves the signs and symptoms of rheumatoid arthritis", Genentech’s chief medical officer, Hal Barron, M.D commented, "These results build on earlier findings from our broad clinical program”.


Ocrelizumab is an investigational humanized monoclonal antibody. According to the treatment’s development partners, Ocrelizumab selectively binds to and eliminates a particular protein, which is believed to play a critical role in immunologic diseases. Subsequently allowing healthy cells to regenerate after treatment and eventually return to normal levels.


The primary endpoint was to determine the proportion of patients with improving signs and symptoms (as measured by American College of Rheumatology) at week 24 and week 48. The results of three other Phase III studies investigating the use of ocrelizumab in RA are expected in the first half of 2010.



Register here to be notified of future BIIB Company articles
View full BIIB profile

Biogen Inc Timeline

Related Articles

GW_Pharma.png
November 22 2016
With the balance sheet now significantly strengthened, we anticipate the company is well-positioned to capture value in areas where its technology platforms offer material improvements for patient care - Panmure Gordon.
picture of drug lab
November 07 2016
The aim is for clinical trials for AP102 to start next year
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC